Recent Developments in Targeted Therapies of the RAF-MEK and PI3KAKT Pathways in Cancer Treatment

Author(s): Lobke G.M. Cremers, Johannes Boonstra

Journal Name: Current Cancer Therapy Reviews

Volume 8 , Issue 3 , 2012

Become EABM
Become Reviewer
Call for Editor


The RAF-MEK and PI3K-AKT pathways are both frequently deregulated in cancer, and often play a critical role in oncogenesis. In the previous years, major progress has been made in the development of targeted drugs against signaling kinases which are involved in carcinogenesis. Currently, targeted drugs against RAF, MEK, PI3K and AKT (among several others) have entered clinical investigation. Here we describe tumor causing mutations of these kinases, as well as the small molecule inhibitors that target these kinases, which contributes to improved ways of treating human cancer.

Keywords: AKT, Antitumor activity, Inhibitors, MEK, PI3K, RAF, Targeted drugs

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 30 August, 2012
Page: [205 - 217]
Pages: 13
DOI: 10.2174/157339412802653209
Price: $65

Article Metrics

PDF: 6